ARCHIVES

FDA Proposes New User Fees for Generics and Biosimilar Products

This article is from The Cancer Letter archive.

Vol. 38 No. 03 | January 20, 2012

Download PDF Visit The Full Archive

Related Articles

GAO Study Claiming No Benefit Seen In Adjuvant Breast Cancer Treatment Flawed, NCI Responds

April 21, 1989

Immunology Grant, Contract Coordination Set; Advice To Applicants-See New Plan

February 8, 1974

NCAB Decides To End IGs, Review total Research Support, And Consider P01 Limitation

June 12, 1992

Oncology ManagementL AOR earns $30 Million, PRN Earns $29.8 Million

March 5, 1999

ACCC To Take In State Chapters, Forms Trials Group

April 6, 1990

Lung Screening Study Ties Up Advisors, Board Sends It Back To NCI For Revision.

June 29, 2001